Welcome to the Love Research Army

The Love Research Army, formerly known as the Army of Women, is committed to encouraging and facilitating breast cancer research in all people, regardless of age, race, gender, sexual identity, with or without a breast cancer diagnosis. We combat the disparities that exist in research by challenging the scientific community to launch studies that are as inclusive and diverse as the people that breast cancer affects. We consistently and intentionally recruit members who are willing and excited to participate in breast cancer research. We are committed to thoughtfully engaging over 380,000 members by providing them with on-going, real-time access to an array of studies.

Love Research Army Advocates

People enrolled in the Love Research Army


As of 9/26/2020


How the Love Research Army Works

The Love Research Army aims to connect women and men of all ages, ethnicities, and locations to researchers committed to solving important breast cancer questions. Our goal is to accelerate and increase diversity in breast cancer research. All supported studies are conducted by research teams around the country and have passed a three-step review process. Learn more here!


Be the first to hear about studies recruiting with the Love Research Army

Current Studies

Learn about all Love Research Army supported research studies


Listen to researchers discuss their studies and results

Your Impact

See how your support has changed the face of breast cancer research


Recent Studies

Genetic and non-genetic factors are believed to influence whether a woman with a BRCA1, BRCA2, and/or PALB2 mutation goes on to develop breast and/or...
Steven Narod
Women's College Research Institute
The purpose of this study is to investigate the relationship between your cardiovascular fitness and your body’s immune response, as both may be...
Janice Kiecolt-Glaser
Ohio State University Institute for Behavioral Medicine Research
The purpose of this study is to investigate whether using Temodar and Kadcyla together decreases the chance of patients with HER2+ metastatic breast...
Alexandra Zimmer